2016
DOI: 10.2337/dc16-1324
|View full text |Cite
|
Sign up to set email alerts
|

Metformin Is Associated With Higher Relative Abundance of Mucin-Degrading Akkermansia muciniphila and Several Short-Chain Fatty Acid–Producing Microbiota in the Gut

Abstract: Our results support the hypothesis that metformin shifts gut microbiota composition through the enrichment of mucin-degrading A. muciniphila as well as several SCFA-producing microbiota. Future studies are needed to determine if these shifts mediate metformin's glycemic and anti-inflammatory properties.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

23
421
5
9

Year Published

2017
2017
2024
2024

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 560 publications
(478 citation statements)
references
References 37 publications
23
421
5
9
Order By: Relevance
“…Interestingly, metformin treatment may improved the glycemic profile modifying gut microbiota, and accumulating evidence suggests that the gut microbiota is an important factor in mediating the development of obesity-related metabolic disorders, including type 2 diabetes [57,58]. For example, high-fat diet (HFD)-fed C57BL/6 mice treated with metformin showed a higher abundance of the mucin-degrading bacterium Akkermansia muciniphila with an increase of the number of mucin-producing goblet cells due to metformin treatment [59,60,61]. Other studies in animal models disclosed an increase of Clostridium cocleatum [60], Butyrivibrio, Bifidobacterium bifidum, and Megasphaera [61].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Interestingly, metformin treatment may improved the glycemic profile modifying gut microbiota, and accumulating evidence suggests that the gut microbiota is an important factor in mediating the development of obesity-related metabolic disorders, including type 2 diabetes [57,58]. For example, high-fat diet (HFD)-fed C57BL/6 mice treated with metformin showed a higher abundance of the mucin-degrading bacterium Akkermansia muciniphila with an increase of the number of mucin-producing goblet cells due to metformin treatment [59,60,61]. Other studies in animal models disclosed an increase of Clostridium cocleatum [60], Butyrivibrio, Bifidobacterium bifidum, and Megasphaera [61].…”
Section: Discussionmentioning
confidence: 99%
“…For example, high-fat diet (HFD)-fed C57BL/6 mice treated with metformin showed a higher abundance of the mucin-degrading bacterium Akkermansia muciniphila with an increase of the number of mucin-producing goblet cells due to metformin treatment [59,60,61]. Other studies in animal models disclosed an increase of Clostridium cocleatum [60], Butyrivibrio, Bifidobacterium bifidum, and Megasphaera [61]. Similar data are hypothesized in human with T2DM [62].…”
Section: Discussionmentioning
confidence: 99%
“…Recent studies suggest that the microorganisms are involved in mediating the beneficial effects of metformin on glucose metabolism. Metformin shifts gut microbiota composition through the enrichment of mucin-degrading A. muciniphila as well as several short- chain fatty acid-producing microbiota including Butyrivibrio , Bifidobacterium bifidum , Megasphaera , and Prevotella (194). Overall, there is substantial evidence of the key role of microbiota in obesity and its adverse effects.…”
Section: Role Of Microbiome In Obesitymentioning
confidence: 99%
“…At the same time, there were reports of a favorable therapeutic effect of the association of metformin and GLP-1 preparations [26], and that of a certain role of microbiota (a set of microbes in the intestine) [9].…”
Section: том 13 № 5 2017mentioning
confidence: 99%